ONR-001
Cancer Persistence (Colorectal Cancer, Melanoma mentioned)
Pre-clinicalActive
Key Facts
Indication
Cancer Persistence (Colorectal Cancer, Melanoma mentioned)
Phase
Pre-clinical
Status
Active
Company
About Oniria Therapeutics
Oniria Therapeutics is an early-stage biotech spin-off from VHIO, UB, and ICREA, pioneering a novel strategy in oncology by modulating cancer cell dormancy. Its lead program, ONR-001, is a first-in-class molecule designed to allosterically activate the epigenetic enzyme TET2, forcing tumor cells into dormancy or death. The company is pre-clinical and pre-revenue, backed by significant non-dilutive public grants from Spanish and EU entities. Its mission is to address the critical unmet need of cancer persistence and recurrence following initial treatment.
View full company profile